IGC Pharma (IGC) Gross Margin (2010 - 2025)

IGC Pharma (IGC) has reported Gross Margin for 16 consecutive years, with 51.83% the latest figure, recorded in Q3 2025.

• On a quarterly basis, Gross Margin rose 377.0% year-over-year to 51.83% in Q3 2025; TTM through Sep 2025 was 46.31%, a 990.0% decrease from a year earlier, with the FY2026 full-year figure at 17.35%, down 3135.0% from the prior year.
• Gross Margin was 51.83% for Q3 2025 at IGC Pharma, up from 46.81% in the prior quarter.
• Over five years, Gross Margin peaked at 67.86% in Q3 2021 and troughed at 30.72% in Q4 2022.
• A 5-year average of 50.5% and a median of 48.06% in 2024 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin soared 4706 bps in 2021 and tumbled 2473 bps in 2024, its largest moves.
• Over 5 years, Gross Margin stood at 43.66% in 2021, then fell by 30 bps to 30.72% in 2022, then jumped by 112 bps to 65.2% in 2023, then plunged by 38 bps to 40.47% in 2024, then grew by 28 bps to 51.83% in 2025.
• The last three Gross Margin figures came in at 51.83% (Q3 2025), 46.81% (Q2 2025), and 46.67% (Q1 2025), per Business Quant data.